In this study, combining the HDAC inhibitor Entinostat with the immunocytokine NHS-rmIL12 achieved significant tumor resolution in three distinct models with a range of immunogenicity and sensitivity to anti-PD-L1 monotherapy, conferring long-lasting protective immunity in all three models. This evidence concerns the gene HDAC9 and neoplasm.